---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-055940"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2026-08-12T11:02:30+00:00"
generated_at: "2026-08-12T11:05:14.280812+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Acumen Q2 2026 net loss $32.7M, cash $110.2M; ALTITUDE-AD topline due late 2026

## Summary
- Net loss $32.7M vs $41.0M in Q2 2025; loss from operations $32.6M.
- Cash and equivalents $110.2M at June 30, 2026, down from $128.4M at March 31; funds into early 2027.
- R&D expenses $27.8M vs $37.1M prior year on lower ALTITUDE-AD manufacturing and CRO costs.
- Expects topline from Phase 2 ALTITUDE-AD (542 participants, 35/50 mg/kg vs placebo) in late 2026.
- Nominated EBD candidates ACU301 and ACU401; IND submission targeted mid-2027.

## SEC filing metadata
- accession: 0001628280-26-055940
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2026-08-12T11:02:30+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000162828026055940/0001628280-26-055940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000162828026055940/abos-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-055940
- JSON: https://secwatch.observer/filing/0001628280-26-055940.json
- Plain text: https://secwatch.observer/filing/0001628280-26-055940.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.